Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Therapy Directory

Lenalidomide clinical trials

Directory of U.S. ClinicalTrials.gov public records that list Lenalidomide as a study intervention. Browse Lenalidomide recruiting trials, filter by phase, sponsor, or location, and open the official ClinicalTrials.gov study record for each result.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 12:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
703
Shown on this page
12
Current sort
Recently updated
Therapy scope
Lenalidomide
Additional filters apply within this therapy.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this therapy

These controls apply only within Lenalidomide. Default order is Recently updated. Add condition, location, sponsor, or recruitment status to narrow this therapy page further.

Reset therapy filters
Clear filters
Showing 517–528 of 703 matching trials for Lenalidomide.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search
Terminated Phase 1Phase 2 Interventional Results available

Phase I/II Trial of the Combination of Lenalidomide (Revlimid) and Nab-paclitaxel (Abraxane) in the Treatment of Relapsed/Refractory Multiple Myeloma

NCT02075021
View directory record Official record
Conditions
Relapsed or Refractory Multiple Myeloma
Interventions
Lenalidomide, nab-paclitaxel
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 15, 2018 · Synced Oct 30, 2026, 12:24 PM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Trial of Bevacizumab, Lenalidomide, Docetaxel, and Prednisone (ART-P) for Treatment of Metastatic Castrate-Resistant Prostate Cancer

NCT00942578
View directory record Official record
Conditions
Metastatic Prostate Cancer
Interventions
Bevacizumab, Lenalidomide, Docetaxel, Prednisone
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 100 Years · Male only
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 11, 2018 · Synced Oct 30, 2026, 12:24 PM EDT
Terminated Phase 2 Interventional Results available

Lenalidomide as Immune Adjuvant in Patient's With Chronic Lymphocytic Leukemia (CLL)

NCT01924169
View directory record Official record
Conditions
Hematologic Disorder
Interventions
Lenalidomide, Influenza Vaccine, Pneumovax Vaccine
Drug · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 20, 2018 · Synced Oct 30, 2026, 12:24 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Lenalidomide and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndromes

NCT00352001
View directory record Official record
Conditions
Leukemia, Myelodysplastic Syndromes
Interventions
azacitidine, lenalidomide
Drug
Lead sponsor
Mikkael Sekeres MD
Other
Eligibility
18 Years to 120 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
3
States / cities
Los Angeles, California • Tampa, Florida • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 19, 2018 · Synced Oct 30, 2026, 12:24 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Phase 1-2 Amrubicin in Combo With Lenalidomide + Weekly Dexamethasone in Relapsed/Refractory Multiple Myeloma

NCT01355705
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Amrubicin, Lenalidomide, Dexamethasone, Aspirin, Pegfilgrastim
Drug
Lead sponsor
Michaela Liedtke
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Sep 18, 2018 · Synced Oct 30, 2026, 12:24 PM EDT
Completed Phase 2 Interventional Results available

Bortezomib Based Consolidation in Multiple Myeloma Patients Completing Stem Cell Transplant

NCT01706666
View directory record Official record
Conditions
Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
Interventions
bortezomib, cyclophosphamide, lenalidomide, laboratory biomarker analysis, dexamethasone, quality-of-life assessment
Drug · Other · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
4
States / cities
Scottsdale, Arizona • Baltimore, Maryland • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2018 · Synced Oct 30, 2026, 12:24 PM EDT
Terminated Phase 2 Interventional Results available

Study of Lenalidomide as a Treatment for Neuropathy Associated With Monoclonal Gammopathy of Undetermined Significance

NCT00665652
View directory record Official record
Conditions
Neuropathy, Nonmalignant Monoclonal Gammopathy of Undetermined Significance (MGUS)
Interventions
Lenalidomide
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Sep 11, 2018 · Synced Oct 30, 2026, 12:24 PM EDT
Completed Early Phase 1 Interventional

Lenalidomide, Dexamethasone and MEDI-551 in Untreated Multiple Myeloma

NCT01861340
View directory record Official record
Conditions
Myeloma
Interventions
Lenalidomide, Dexamethasone, and MEDI-551
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 100 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 10, 2018 · Synced Oct 30, 2026, 12:24 PM EDT
Terminated Phase 1 Interventional

Palbociclib in Combination With Lenalidomide and Dexamethasone for Multiple Myeloma

NCT02030483
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Palbociclib, Dexamethasone, Lenalidomide
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 22, 2018 · Synced Oct 30, 2026, 12:24 PM EDT
Completed Phase 2 Interventional Results available

Lenalidomide as Initial Treatment of Patients With Chronic Lymphocytic Leukemia (CLL) Age 65 and Older

NCT00535873
View directory record Official record
Conditions
Leukemia, CLL, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions
Lenalidomide
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
65 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 21, 2018 · Synced Oct 30, 2026, 12:24 PM EDT
Completed Phase 2 Interventional Results available

Pomalidomide or Lenalidomide and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma Previously Treated With Lenalidomide

NCT01794039
View directory record Official record
Conditions
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Interventions
Dexamethasone, Lenalidomide, Pomalidomide
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 21, 2018 · Synced Oct 30, 2026, 12:24 PM EDT
Completed Phase 2 Interventional Results available

Phase 2 Multi-center Study of Anti-PD-1 During Lymphopenic State After HDT/ASCT for Multiple Myeloma

NCT02331368
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Autologous Stem Cell Transplant, Melphalan, Lenalidomide, MK-3475
Procedure · Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years to 75 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
2
States / cities
Ann Arbor, Michigan • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 27, 2018 · Synced Oct 30, 2026, 12:24 PM EDT

About this Lenalidomide clinical trials directory page

What this page lists
U.S. ClinicalTrials.gov public records that list Lenalidomide as a study intervention, including recruiting, not yet recruiting, and active not recruiting trials.
How to narrow results
Use the filters above to scope by condition, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Lenalidomide.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Related: all therapy pages, browse by condition, browse by U.S. city, browse by sponsor, or open the full search for Lenalidomide.